Outcomes of Older Patients With Cardiogenic Shock Using the Impella Device ― Insights From the Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) ―
Authors:
- Ryosuke HiguchiRHRyosuke Higuchi
- The J-PVAD InvestigatorsTIThe J-PVAD Investigators
Open Access
- 8 November 2024
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 6 (11) , 505-513
Abstract
Background: Aging has progressed in several regions of the world with more older patients experiencing acute cardiovascular disease. Impella is a percutaneous potent circulatory support device associated with substantial cost and potential device-related complications.Methods and Results: We analyzed the Japanese nationwide registry, encompassing consecutive patients with cardiogenic shock using Impella. Among 5,718 patients treated between 2020 and 2022, we compared older patients (≥75 years) with younger patients. The primary outcome was the Kaplan-Meier estimated 30-day mortality, and the secondary outcome was Impella-related complications. The median age of the 5,718 patients was 69 (58–77) years, and 1,807 (31.6%) were older, with smaller body mass index, frequent acute coronary syndrome, and infrequent myocarditis. Comorbidities were frequently observed in older patients with a higher ejection fraction and less frequency of extracorporeal membrane oxygenation. Older patients had a higher 30-day mortality than younger patients (38.9% vs. 32.5%; P<0.0001). The 30-day mortality was statistically equivalent among older subsets (75–79 vs. 80–84 vs. ≥85 years). Device-related complications similarly occurred similarly among the older subsets, except for a modest increase in cardiac tamponade and limb ischemia. Older age, body mass index, myocarditis, prior arrhythmia, shock severity, renal and hepatic impairment, and limb ischemia were associated with 30-day mortality.Conclusions: The selected older patients using Impella exhibited modestly higher 30-day mortality with similar safety profiles. A longer follow up and optimal patient selection are important.Keywords
This publication has 24 references indexed in Scilit:
- Chronological vs Biological Age in Interventional CardiologyJACC: Cardiovascular Interventions, 2024
- Management of Bleeding and Hemolysis During Percutaneous Microaxial Flow Pump SupportJACC: Cardiovascular Interventions, 2023
- Assessment and Management of Older Adults Undergoing PCI, Part 1JACC: Advances, 2023
- Impact of Frailty on Outcomes After Transcatheter Edge-to-Edge Repair With MitraClip (from the National Inpatient Sample Database)The American Journal of Cardiology, 2022
- Procedural Success Rates and Mortality in Elderly Patients With Percutaneous Coronary Intervention for Cardiogenic ShockJACC: Cardiovascular Interventions, 2019
- Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Elderly Patients: Trends in Application and Outcome From the Extracorporeal Life Support Organization (ELSO) RegistryThe Annals of Thoracic Surgery, 2017
- Long-term survival of elderly patients undergoing percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shockInternational Journal of Cardiology, 2015
- Heart Failure as a General Pandemic in AsiaEuropean Journal of Heart Failure, 2015
- Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial RegistryEuropean Heart Journal, 2003
- Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic ShockNew England Journal of Medicine, 1999